Related Experiment Video
Updated: May 9, 2026
Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
Published on: February 3, 2021
Development of a screen to identify selective small molecules active against patient-derived metastatic and
Introduction:
High failure rates of new investigational drugs have impaired the development of breast cancer therapies. One challenge is that excellent activity in preclinical models, such as established cancer cell lines, does not always translate into improved clinical outcomes for patients. New preclinical models, which better replicate clinically-relevant attributes of cancer, such as chemoresistance, metastasis and cellular heterogeneity, may identify novel anti-cancer mechanisms and increase the success of drug development.
Methods:
Metastatic breast cancer cells were obtained from pleural effusions of consented patients whose disease had progressed. Normal primary human breast cells were collected from a reduction mammoplasty and immortalized with human telomerase. The patient-derived cells were characterized to determine their cellular heterogeneity and proliferation rate by flow cytometry, while dose response curves were performed for chemotherapies to assess resistance. A screen was developed to measure the differential activity of small molecules on the growth and survival of patient-derived normal breast and metastatic, chemoresistant tumor cells to identify selective anti-cancer compounds. Several hits were identified and validated in dose response assays. One compound, C-6, was further characterized for its effect on cell cycle and cell death in cancer cells.
Results:
Patient-derived cells were found to be more heterogeneous, with reduced proliferation rates and enhanced resistance to chemotherapy compared to established cell lines. A screen was subsequently developed that utilized both tumor and normal patient-derived cells. Several compounds were identified, which selectively targeted tumor cells, but not normal cells. Compound C-6 was found to inhibit proliferation and induce cell death in tumor cells via a caspase-independent mechanism.
Conclusions:
Short-term culture of patient-derived cells retained more clinically relevant features of breast cancer compared to established cell lines. The low proliferation rate and chemoresistance make patient-derived cells an excellent tool in preclinical drug development.
Insights
Patient-derived cells better model breast cancer's chemoresistance and heterogeneity than standard cell lines. These models can identify selective anti-cancer drugs, improving drug development success rates.
Area of Science:
- Oncology
- Cancer Biology
- Drug Development
Background:
- High failure rates in breast cancer drug development are linked to preclinical models that don't reflect clinical cancer attributes.
- Developing new preclinical models that mimic chemoresistance, metastasis, and heterogeneity is crucial for identifying novel anti-cancer mechanisms.
Purpose of the Study:
- To establish and utilize patient-derived cells as a more clinically relevant preclinical model for breast cancer drug discovery.
- To identify selective anti-cancer compounds that target tumor cells while sparing normal cells.
Main Methods:
- Metastatic breast cancer cells and normal breast cells were obtained from patients and healthy donors, respectively.
- Patient-derived cells were characterized for heterogeneity, proliferation, and chemoresistance.
- A small molecule screen was developed to identify compounds selectively targeting tumor cells.
Main Results:
- Patient-derived cells exhibited greater heterogeneity, reduced proliferation, and enhanced chemoresistance compared to established cell lines.
- The screen identified several compounds selectively inhibiting tumor cell growth and survival.
- Compound C-6 demonstrated inhibition of proliferation and induced cell death in cancer cells via a caspase-independent pathway.
Conclusions:
- Short-term cultured patient-derived cells retain clinically relevant features of breast cancer, outperforming established cell lines.
- These patient-derived models are valuable tools for preclinical drug development, aiding in the identification of effective anti-cancer agents.
